



NEWS RELEASE

PALADIN SUBMITS PATENT APPLICATION FOR THINSOL™, A NOVEL ORAL INGESTIBLE FILM COMPOSITION DELIVERY SYSTEM

Montreal, Canada, November 6, 2007 – Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced that it has submitted a patent application for its novel oral ingestible film composition delivery system, Thinsol™. Thinsol™ is a water-based, enzymatically-digested carboxymethylcellulose (CMC-enz) film that is suitable for the rapid delivery of pharmaceutical and nutraceutical active ingredients.

Thinsol™ may offer significant advantages over current edible film technologies. BioEnvelop's™ research has determined that use of the Thinsol™ delivery technology allows for the development of products that others may not be able to formulate in a film strip format, such as products that are heat-sensitive and those that require high drug loads on each strip.

Specifically, Thinsol™ can accommodate active ingredients in a quantity of up to 60% of the overall weight of the film, allowing for development of a film strip containing over 100mg of active ingredients. Currently, the largest amount of active ingredients in a commercial film strip is 60mg.

In addition, unlike most film strip technology, Thinsol™ does not require heat during the manufacturing process. Using Thinsol™, films can be dried at low temperatures from sources such as hot air or infrared technology, which allows for greater product opportunities for drugs that are heat-sensitive or labile. Consequently, Thinsol™ offers an alternative that may not have been available to drug manufacturers.

“Thinsol™ is fast dissolving, it leaves no residue in the mouth, being a water-based system, there is no need for the use of alcohol or other solvents during its production and it can be dried at low temperatures,” said Etan Jagermann, Chief Operating Officer of BioEnvelop™. “This technology opens up a whole new source of product opportunities for BioEnvelop™.”

About BioEnvelop™

BioEnvelop™ researches, develops, manufactures, and markets innovative health care products in both edible film and gel formats. BioEnvelop™ has a license to manufacture under the Natural Health Products (NHP) certification program of Canada. BioEnvelop™ continues to offer many new opportunities for nutraceutical companies to change from a tablet or capsule format into a gel or edible film strip. In either case, BioEnvelop™ has the passion, the resources and the complete focus to execute the introduction of a new product delivery concept to the marketplace and is constantly looking for new technologies and partnerships.

For further information about BioEnvelop™ please visit the Company's web site at www.bioenvelop.com.

About Paladin Labs Inc

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol *PLB*. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.

This news release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2006. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other filings found on SEDAR at www.sedar.com.

For more information, please contact:

Samira Sakhia
Chief Financial Officer
Paladin Labs Inc.
Tel: (514) 340-5067
Fax: (514) 344-4675
Email: info@paladin-labs.com
Website: www.paladinlabs.com

Etan Jagermann
Chief Operating Officer
BioEnvelop™
Tel: (514) 340-5079
Fax: (514) 344-4675
Email: ejagermann@paladin-labs.com
Website: www.paladinlabs.com